Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Lamb

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Cancer|April 3, 2007
Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostateAnthony V D'Amico, James W Denham, Michel Bolla, et al.
The New Zealand Medical Journal|November 9, 2018
A prospective audit of the 10-year outcomes from low dose-rate brachytherapy for early stage prostate cancerDavid S Lamb, Lynne Greig, Grant Russell, et al.
Clinical Proteomics|September 22, 2015
Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic diseaseJonathan C Dunne, David S Lamb, Brett Delahunt, et al.
The Lancet. Oncology|November 25, 2011
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trialsAnthony V D'Amico, Ming-Hui Chen, Mario de Castro, et al.
BMC Cancer|December 3, 2009
A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trialDaniel A Galvão, Nigel Spry, Dennis R Taaffe, et al.
European Urology|October 12, 2013
A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADARDaniel A Galvão, Nigel Spry, James Denham, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 11, 2008
PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?James W Denham, David S Lamb, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 4, 2011
Another form of subgroup to bewareJames W Denham, David S Lamb, David Joseph, et al.
The New Zealand Medical Journal|August 23, 2014
A comparison of cancer statistics in New Zealand and Australia: 1996-2007John Waldon, David S Lamb, Brett Delahunt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 16, 2003
The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neckTiffany Daly, Michael G Poulsen, James W Denham, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Cancer|April 3, 2007
Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostateAnthony V D'Amico, James W Denham, Michel Bolla, et al.
The New Zealand Medical Journal|November 9, 2018
A prospective audit of the 10-year outcomes from low dose-rate brachytherapy for early stage prostate cancerDavid S Lamb, Lynne Greig, Grant Russell, et al.
Clinical Proteomics|September 22, 2015
Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic diseaseJonathan C Dunne, David S Lamb, Brett Delahunt, et al.
The Lancet. Oncology|November 25, 2011
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trialsAnthony V D'Amico, Ming-Hui Chen, Mario de Castro, et al.
BMC Cancer|December 3, 2009
A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trialDaniel A Galvão, Nigel Spry, Dennis R Taaffe, et al.
European Urology|October 12, 2013
A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADARDaniel A Galvão, Nigel Spry, James Denham, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 11, 2008
PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?James W Denham, David S Lamb, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 4, 2011
Another form of subgroup to bewareJames W Denham, David S Lamb, David Joseph, et al.
The New Zealand Medical Journal|August 23, 2014
A comparison of cancer statistics in New Zealand and Australia: 1996-2007John Waldon, David S Lamb, Brett Delahunt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 16, 2003
The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neckTiffany Daly, Michael G Poulsen, James W Denham, et al.
Pageof 5